Results 71 to 80 of about 22,516 (228)
Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use
The Prostate, EarlyView.ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley +1 more source
Identifying the role of lncRNAs in CRPC
, 2022 Long non-coding RNAs (lncRNAs) play major roles in the development of cancer, as many of them are implicated in cell growth and tumor-suppressing mechanisms.
Nguyen, Steven
core
Advanced Science, 2023 The development of castration‐resistant prostate cancer (CRPC) is a significant factor that reduces life expectancy among patients with prostate cancer.
Huaiyuan Liang +7 more
doaj +1 more source
The British Journal of Sociology, EarlyView.ABSTRACT The article presents a sociological study of promise‐to‐marry ‘rape’ cases in India to illuminate the inner lives of intimacies. It argues that promise‐to‐marry cases cannot be understood merely as instances of deceptive sex, wherein the consent of the victim is vitiated by a false promise of marriage as a pretext for sexual intercourse ...
Monika
wiley +1 more source
Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC
BJU International, EarlyView.Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics +9 more
wiley +1 more source
BMC CancerBackground The tumor microenvironment (TME) is increasingly acknowledged as a determinant in the malignant transformation and progression of castration-resistant prostate cancer (CRPC).
Yifeng Qiu +5 more
doaj +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, Volume 600, Issue 19, Page 2850-2873, October 2026.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source
Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer
Frontiers in Oncology, 2019 Purpose: Most prostate cancers (PCs) initially respond to androgen deprivation therapy (ADT), but eventually many PC patients develop castration resistant PC (CRPC).
In-Wha Kim, Jae Hyun Kim, Jung Mi Oh
doaj +1 more source
Advanced Science, Volume 13, Issue 56, 9 October 2026.Single‐cell longitudinal profiling reveals that androgen‐deprivation therapy induces a DPT+ fibroblast‐complement axis that suppresses macrophage inflammation and drives CD8+ T cell exhaustion in prostate cancer. Concurrently, resistant epithelial subpopulations persist and engage TSPAN1‐ and NRXN1‐mediated programs promoting CRPC and neuroendocrine ...
Yang Chen +19 more
wiley +1 more source